Today: 30 June 2026
Browse Category

NASDAQ:RANI 17 October 2025 - 28 November 2025

RANI Stock Today, 28 November 2025: Price Action, Options Expiry and Outlook After the $1 Billion Chugai Deal

RANI Stock Today, 28 November 2025: Price Action, Options Expiry and Outlook After the $1 Billion Chugai Deal

Rani Therapeutics Holdings, Inc. is finishing November with quieter headlines but still very lively trading. As of today, 28 November 2025, the biotech micro‑cap is consolidating after its spectacular October surge on the back of a transformative collaboration with Japan’s Chugai Pharmaceutical and a $60.3 million private placement that extended its cash runway into 2028. Reuters+2Stock Titan+2 Crucially for anyone looking for “RANI stock news today”:
28 November 2025
··
Rani Therapeutics (RANI) Stock Skyrockets on Biotech Breakthrough: Inside the Surge and What’s Next

Rani Therapeutics (RANI) Stock Skyrockets on Biotech Breakthrough: Inside the Surge and What’s Next

Rani Therapeutics’ stock price has been on a tear in late 2025, turning heads in the biotech investing community. After languishing under $1 for most of the year, RANI exploded upward in October. It closed on Oct 31 at $2.20, up +51.7% in one dayfinviz.com on massive volume. In fact, over the past month RANI has climbed about 335%finviz.com. Just a few weeks ago in early October it was trading around 50–60 cents; by the first week of November it’s oscillating in the mid-$2s. As of Nov 3, the stock is indicated around $2.50futunn.com – a stunning short-term gain, though still a far cry from its IPO price. Such parabolic moves have made RANI a momentum play. The catalyst was the mid-October announcement of a landmark partnership which injected optimism into Rani’s prospects. In the days following the news, traders on social media highlighted the “massive spike” – RANI was up 200–280% at one point – as evidence of excitement around Rani’s oral biologics platformquiverquant.com. This momentum continued through late October as positive sentiment built. By the end of the month, RANI was a regular mention on “top gainer” lists, albeit with high volatility.
3 November 2025
··
Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

Rani Therapeutics Stock Explodes on Obesity-Drug Breakthrough – Analysts Eye $10+ Targets

Rani shares have exploded in the last month. On Oct 1, 2025 RANI traded around $0.50. A landmark collaboration announced Oct 17 with Japan’s Chugai and a simultaneous $60M financing sent the stock soaring. Intraday Oct 17 it jumped from $0.47 to $2.39ts2.tech. By Oct 31 the stock closed at $2.20, a 51.7% gain on that day alonets2.tech. This means RANI is up roughly +20% in the past week and about +330% in Octoberinvesting.cominvesting.com.This rally propelled RANI well above Nasdaq’s $1 minimum bidts2.tech. Volatility and volume have been extreme: in mid‑October daily volume hit 100–200 million sharests2.tech. All told, RANI’s late‑Oct performance turned it from a near-penny stock into a mid-cap biotech in two weeks. Oct 17, 2025: Rani announced a collaboration and license deal with Chugai Pharmaceutical for an undisclosed rare-disease antibody program. The deal could pay Rani up to $1.085 billionts2.tech. This landmark pact makes Rani, a once-sub-$1 stock, central to Japan’s pharma innovation. Reuters noted the deal “potentially valuing the collaboration at $1.09 billion”reuters.com. In comments, Chugai’s research head Dr. Tomoyuki Igawa said Rani’s technology “opens up new possibilities for the administration of biologics… we expect to create entirely new value in the form of oral therapies”ts2.tech.
1 November 2025
·
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Rockets 51% on Obesity Pill Breakthrough and $1B Pharma Deal

RANI has seen explosive moves this month. As of the Oct 31 close, Rani Therapeutics stock was $2.20stockanalysis.com. This follows a monumental rally: on Oct 17, RANI nearly tripled from ~$0.47 to an intraday high of $2.39ts2.techstockanalysis.com after the company announced the Chugai collaboration and financing. Even after that spike, RANI remained volatile – it spent mid-October around $1.50–2.50, briefly crossing Nasdaq’s $1 bid threshold and greatly lifting its market cap. Volume has been extremely high: for example, ~172 million shares traded on Oct 20 and ~124 million on Oct 21stockanalysis.com, versus an average of only ~14 million in prior monthstipranks.com. In recent days, RANI dipped as low as ~$1.42 but rebounded sharply on Oct 31. Year-to-date the stock is still well off its 2021 highs, but the October news has put it in breakout mode. Several catalysts drove the recent moves. On Oct 17, 2025, Rani announced a landmark licensing agreement with Chugai Pharmaceutical: an up to $1.09 billion deal for an oral biologic programreuters.comts2.tech. At the same time Rani disclosed a heavily oversubscribed $60.3M private placement at $0.48/share led by Samsara BioCapitalir.ranitherapeutics.comts2.tech. Together these moves greatly extend Rani’s runway.
31 October 2025
··
Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

Rani’s stock price skyrocketed after the company unveiled its landmark partnership and financing news. On Friday, Oct. 17, 2025, RANI opened around $1.37 and surged as high as $2.39 intraday before settling at a $1.64 closing price – a stunning +248% one-day gain investing.com. The prior day, RANI had closed at just $0.47, so the news sparked an almost threefold leap in value. In pre-market trading before the open, the stock had already jumped over +150%, and it continued to rally after the bell ts2.tech ts2.tech. By midday Oct. 17, shares were still trading around the $1.30 level, prompting observers like TechStock² to note that Rani had “snapped out of penny-stock territory” and climbed back above Nasdaq’s minimum $1 bid price, easing near-term delisting fears ts2.tech ts2.tech. Such a dramatic spike in price was accompanied by unusually heavy trading volume, reflecting a frenzy of investor interest. Roughly 70 million shares of RANI changed hands on Oct. 17 – an astronomical jump from the stock’s meager ~318,000 share average volume over the prior months ts2.tech. This kind of trading mania suggests many traders piled in on the breaking news, driving the price volatility. Notably, Rani’s stock had been in a deep
20 October 2025
·
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics, a clinical-stage biotech developing the RaniPill® capsule for oral delivery of biologic drugs, was essentially flat around $0.45–$0.50 from mid-September through early October. On Oct. 17, it announced a collaboration with Chugai to turn one of Chugai’s injectable rare-disease antibodies into a pill formulation. The news, coupled with the new funding, ignited a buying frenzy ts2.tech. By mid-day Friday, RANI was up ~180% on the session ts2.tech, markedly outpacing the broader market’s modest gains. Deal Details: Under the Chugai pact, Rani gets $10M upfront, up to $75M in tech-transfer/development milestones and up to $100M in sales milestones, plus royalties investing.com. If Chugai exercises options on five more drugs, Rani stands to collect an additional ~$900M. Rani’s press release and Dow Jones report note that this sum is transformational for a company whose market cap is only ~$40–50 million ts2.tech. Rani’s CEO Imran said the deal “represents a convergence of Rani’s...oral delivery platform and Chugai’s expertise” and offers a chance to develop “a transformative oral therapy” for rare diseases ir.ranitherapeutics.com. Chugai’s Igawa added that integrating Rani’s technology will “accelerate our challenge to realize advanced, patient-centric healthcare” ir.ranitherapeutics.com.
18 October 2025
···
Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Rani Therapeutics (RANI) Stock Nearly Triples on $1B Chugai Deal – What Investors Should Know

Rani Therapeutics’ stock price erupted on Friday, Oct. 17, 2025, after the company unveiled its game-changing pharma partnership and a significant financing boost. In pre-market trading, RANI shares jumped over +150%, and the rally continued after the opening bellts2.techts2.tech. The stock — which had closed at just $0.47 the day before — briefly hit about $1.37 intraday on extremely heavy volumets2.techts2.tech. By midday, RANI was still trading around $1.30, up ~180% on the day, marking a stunning one-day surge that lifted the stock out of penny-stock territoryts2.tech. Such an explosive move was accompanied by a frenzy of trading. Approximately 70 million RANI shares changed hands on Oct. 17 – a staggering spike compared to the stock’s meager 3-month average of around 318,000 shares per dayts2.tech. This suggests intense speculative interest, as traders piled into the stock on the breaking news. Notably, even after soaring nearly 200%, RANI’s price was still down roughly 65% year-to-date and over 80% below its level one year agots2.tech, underscoring how beaten-down the stock had been before this turnaround. By closing at $1.64, Rani also regained compliance with Nasdaq’s $1.00 minimum bid requirement, easing imminent delisting worriests2.tech.
18 October 2025
···
Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Rani Therapeutics’ stock price skyrocketed on Friday, Oct. 17, after the company unveiled a major partnership and funding news. In pre-market trade, RANI jumped about 150% and continued to rally after the market open tipranks.com. The stock, which had closed at just $0.47 the prior day, briefly hit approximately $1.37 per share – nearly a 3× gain in value google.com. By midday, shares were still trading around the $1.30 level, up almost +180% on the day. This stunning one-day move snapped RANI out of penny-stock territory and back above the Nasdaq’s $1 minimum bid price, easing near-term delisting fears. Such a dramatic spike in price was accompanied by unusually heavy trading volume, indicating intense investor interest. About 70 million RANI shares changed hands on Oct. 17 – an astonishing jump compared to the stock’s modest three-month average of ~318,000 shares per day tipranks.com. The frenzy reflects traders piling in on breaking news. Notably, RANI had been in a long slump prior to this surge: even after the pop, shares remain down about 65% year-to-date and over 80% below their levels a year ago tipranks.com. This context shows how badly the stock had been beaten down – and how transformative the
17 October 2025
···

Stock Market Today

  • Canadian Natural Resources (TSX:CNQ) Dividend Yield Climbs as Shares Fall
    June 29, 2026, 9:38 PM EDT. Canadian Natural Resources (TSX:CNQ) is trading about 20% below recent highs, which has pushed its dividend yield up from 3.5% to near 4.5%. The company is known for low operating costs, steady cash flow, and ongoing dividend increases and buybacks. Oil prices are still choppy, but management expects to keep growing free cash flow and to boost returns to shareholders from 75% up to 100% over the next year to 18 months. Buying now gives investors a higher yield if the stock recovers.
Go toTop